CAR-T Cell Therapy vs. Bispecific Antibody Therapies in Relapsed Lymphoma скачать в хорошем качестве

CAR-T Cell Therapy vs. Bispecific Antibody Therapies in Relapsed Lymphoma

Subscribe to our channel, and turn on notifications (🔔)! https://bit.ly/3bNnYgN The prognosis for relapsed/refractory large B cell lymphoma has historically been poor. Three novel CAR-T cell therapies are showing curative potential. Who we are Figure 1 is a digital platform that allows users to share clinical cases with each other for educational purposes. Check out https://www.figure1.com . You can also download our apps here: iOS: https://apple.co/2XglLDu Android: https://bit.ly/3aGLmbP Follow us in these places YouTube: https://bit.ly/3zKXqES Twitter: https://bit.ly/3QdDZeT Facebook: https://bit.ly/3QtQ4MJ Instagram: https://bit.ly/3bJ1NIM Medical Disclaimer Figure 1 and Figure 1’s properties (Figure1.com, YouTube, Figure 1 mobile app, and other channels) are primarily educational tools and are not intended to serve the following needs: as a diagnostic service; as a confirmatory service to provide certainty in diagnosis; to select, guide, or promote therapy of medical conditions; for use in hazardous or mission-critical circumstances or for uses requiring fail-safe performance; or in situations where failure could lead to death or personal injury (collectively, “unauthorized purposes”). The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed health care provider. Always seek the advice of a physician or other qualified healthcare provider with any questions you have regarding a medical condition.